Today marks the 30th anniversary of an event that kicked off an important new era in drug therapies – the approval by the FDA of human insulin synthesized in genetically engineered bacteria.
Read this article:
The Roots Of The Anti-Genetic Engineering Movement? Follow The Money!
By Jay Byrne and Henry I. Miller
Read the original post:
The Roots Of The Anti-Genetic Engineering Movement? Follow The Money!
(301) 337-2100 "Gene Therapy Rockville, 20850" "Cell therapy Rockville, 20850" – Video
(301) 337-2100 "Gene Therapy Rockville, 20850" "Cell therapy Rockville, 20850"
http://www.AmericanGeneTechnologies.com American Gene Technologies International Inc. (AGTII) is developing bio-safe, high efficiency lentivirus therapies to treat cancer and other chronic human diseases. AGTII was founded in 2007 to develop bio-safe, high-efficiency, multi-gene vectors for human gene delivery in-vivo. AGTII #39;s products incorporate a novel, proprietary technology for the clinical application of gene expression technology in cancer therapy, autosomal disorders, stem cell treatment, and cosmetic applications. In vivo studies completed at the University of Maryland have demonstrated the efficacy of AGTII #39;s prototype prostate cancer therapeutic by eliminating Human Prostate Cancer tumors in mouse hosts. The active treatment group showed complete resolution of disease without harm to healthy tissue - even in large, late-stage tumors. AGTII also has prototype therapeutics in testing for Pancreatic Cancer. These prototypes have demonstrated efficacy in In vitro testing, as well. Additional designs for therapeutics addressing other cancers are in the design phase. AGTII #39;s vision is to use its technology to enable the one hundred billion dollar genetic drug market. CONTACT US! American Gene Technologies International Inc. Maryland Technology Development Center 9700 Great Seneca Highway Rockville, MD 20850 Phone: (301) 337-2100 Fax: (301) 337-2101 Email: info@agtii.com ----------------------------------------------------- Produced by: Create A Social Buzz SEO Social ...From:CreateAsocialBuzzViews:16 0ratingsTime:01:38More inScience Technology
Read this article:
(301) 337-2100 "Gene Therapy Rockville, 20850" "Cell therapy Rockville, 20850" - Video
Gene therapy – Video
Gene therapy
Short stop motion animationFrom:1234ie1Views:14 0ratingsTime:01:17More inEducation
Read the original here:
Persuasive Speech- Gene Therapy – Video
Persuasive Speech- Gene Therapy
From:Ryan MontalvoViews:4 0ratingsTime:03:36More inHowto Style
See original here:
Nonviral Vectors For Gene Therapy, Part 2 – Video
Nonviral Vectors For Gene Therapy, Part 2
ll4.me Nonviral Vectors For Gene Therapy, Part 2 EAN/ISBN : 9780080456133 Publisher(s): Elsevier Science Technology, Academic Press Format: ePub/PDF Author(s): Huang, Leaf EAN/ISBN : 9780080456133 Publisher(s): Elsevier Science Technology, Academic Press Format: ePub/PDF Author(s): Huang, LeafFrom:andrewmclellan2145Views:3 0ratingsTime:00:14More inPeople Blogs
Read this article:
Genetics and Biotechnology (A Mini-Documentary) – Video
Genetics and Biotechnology (A Mini-Documentary)
*NO COPYRIGHT INFRINGEMENT INTENDED* Narrative(yes I wrote it all by myself based on 2 hours worth of videos): DNA screening could prevent many diseases, gene therapy could cure them and, thanks to lab-grown organs, the human body could be repaired as easily as a car, with spare parts readily available. Ultimately, the ageing process itself could be slowed down or even halted. Hi I #39;m Joyeuphonium and today I #39;ll be looking at the revolution in genetics and biotechnology, which promises unprecedented health and longevity but also raises the spectre of a Frankenstein future of genetically engineered people. Will we, as transhumanists expect, evolve into a new species? Well, here goes nothing~ *intro clip* Genetics of the past: (Age of Scientific Discovery) Gregor Mendel #39;s work on pea plants in the 1850s may have pioneered the field of genetics but it wasnt until the discovery of chromosomes that really did set things off. In between during the 1900s, Thomas Hunt Morgan found that genes are located on chromosomes and some may be sex linked while working on fruit flies. 10 years after that, Beadle and Tatum who were working on bread mold, came up with the #39;one gene one enzyme #39; hypothesis and a further 10 years we find that Barbara McClintork discovered transposons which may cause genes to mutate. Later, the Hershey and Chase experiment was able to conclude that DNA is the genetic material just by using a blender, and then comes the infamous Watson and Crick model of a DNA ...From:joyeuphViews:97 0ratingsTime:04:23More inScience Technology
Link:
[91VOA]Gene Therapy Used to Treat Cancer – Video
[91VOA]Gene Therapy Used to Treat Cancer
English language lessons from the audio and transcript of the Voice of America. VOA Special English helps you learn English with lesson plans, grammar lessons, news and activities.From:91VOAChannelViews:1 0ratingsTime:04:14More inEducation
See the original post:
David Levy CNN iReport Article – Gene Therapy: Cure for the Future? – Video
David Levy CNN iReport Article - Gene Therapy: Cure for the Future?
Gene Therapy: Cure for the Future? Full Acticle - ireport.cnn.com David Levy on Facebook - http://www.facebook.com Animation Short Film: Gene Therapy in Thalassemia Major Patients - http://www.youtube.com Subscibe to my Video Blog Channel - http://www.youtube.com Subscibe to my Podcast Channel - http://www.youtube.com My Official Website - http://www.thalassemianme.org Website - http My Blog - thalassemianme.blogspot.sg Add me on Facebook - https Like me on Facebook - http://www.facebook.com Twitter - twitter.com Google + - plus.google.comFrom:SuperYoutub8Views:13 1ratingsTime:03:20More inPeople Blogs
Excerpt from:
David Levy CNN iReport Article - Gene Therapy: Cure for the Future? - Video
Sickle Cell Anemia gene therp step – Video
Sickle Cell Anemia gene therp step
Dr lelbouch explain gene therapy in the case of sickle celle disease.From:dan mart wedoViews:12 0ratingsTime:01:49More inEducation
Original post:
Dr. Shoukhrat Mitalipov explains his gene therapy method to prevent several childhood diseases – Video
Dr. Shoukhrat Mitalipov explains his gene therapy method to prevent several childhood diseases
From:OHSUvideoViews:26 0ratingsTime:03:46More inNonprofits Activism
Follow this link:
Gene Therapy and Synthetic Biology – Video
Gene Therapy and Synthetic Biology
How the relatively young field of synthetic biology is changing the older field of gene therapy. Produced by UIUC iGEM 2012From:iGEMHPCollaborationViews:10 0ratingsTime:06:05More inEducation
Read more:
21 Molecular Medicine—Gene Therapy – Video
21 Molecular Medicine mdash;Gene Therapy
From:jeffrey727Views:0 0ratingsTime:31:27More inEducation
Go here to read the rest:
27-Medical BiotechnologySG Part II.Gene Therapy, Tissue Engineering and Nanotechnology.mov – Video
27-Medical BiotechnologySG Part II.Gene Therapy, Tissue Engineering and Nanotechnology.mov
In theory, gene therapy offers a straight forward to the molecular treatment of various diseases, by using genes to prevent or treat disease by: Replacing a mutated gene(s) with a healthy copy; Inactivating/knocking out a mutated gene; or, Introducing new gene. Gene Therapy offers an approach to treating disease by either modifying the expressions of an individual #39;s genes or correction of abnormal genes. While this seems straight forward (ie replace or supply a healthy insulin gene in pancreatic cells of a diabetic) it has been difficult to actualize. Think here also about dual use problems (ie genetic doping for athletes, genetic modification enhancement for military personnel, and germline genetic engineering of humans with heritable genes). in this section we also review tissue engineering and some of the possibilities for nanotechnologies in medical devices. Nanosized GPS capable computers in our bloodstream?From:Albert KauschViews:2 0ratingsTime:37:43More inEducation
Read the original here:
27-Medical BiotechnologySG Part II.Gene Therapy, Tissue Engineering and Nanotechnology.mov - Video
Researchers Test New Gene Therapy Method in Human Cells… And It Works – Video
Researchers Test New Gene Therapy Method in Human Cells... And It Works
Researchers at the university #39;s Oregon National Primate Research Center and the OHSU Department of Obstetrics Gynecology have successfully demonstrated their procedure in human cells. It #39;s believed that this research, along with other efforts, will pave the way for future clinical trials in human subjects. Full report available at Scicasts via: s.scicasts.com [Video produced by Oregon Health Science University.]From:scicastsViews:1 0ratingsTime:03:46More inScience Technology
Continued here:
Researchers Test New Gene Therapy Method in Human Cells... And It Works - Video
Bluebird bio lands $9.3M for study
Cambridge-based gene therapy developer bluebird bio said today it has been awarded $9.3 million from the California Institute for Regenerative Medicine to support a Phase 1/2 study for the companys product LentiGlobin, which is designed to treat a group of inherited blood disorders.
The study will be initiated in the United States next year.
LentiGlobin introduces a full functional human beta-globin gene into the patients own hematopoietic stem cells, which ultimately produce fully functioning red blood cells. The company is currently conducting a Phase 1/2 trial examining the feasibility, safety and efficacy of LentiGlobin in treating beta-thalassemia and sickle cell disease.
The CIRM award is among the first awards under the agencys Strategic Partnership Awards initiative, which is designed to engage more effectively with industry and increase outside investment in CIRM-funded stem cell research.
See the rest here:
Gene therapy procedure announced in Oregon could curb hereditary diseases, raise ethical questions
Researchers at Oregon Health & Science University say they have perfected a new gene therapy that could block the transmission of many inherited diseases from mother to child.
But the procedure could raise new ethical questions over genetically engineering offspring.
Already tested in monkeys, the technique replaces defective genetic material in a mother's egg cells before it is fertilized and implanted in the womb. In the new study, published in the journal Nature, researchers used 106 human egg cells obtained from volunteers.
If proven safe, the technique could be used to eliminate genetic dispositions toward diabetes, deafness and eye disorders, along with dementia, heart disease and neuropathy.
It would also give scientists the power to, for the first time, permanently alter the genetic material of future generations.
OHSU is already discussing the potential for human clinical trials with federal regulators, according to Shoukrat Mitalipov, the lead researcher.
Stay tuned for a fuller account later today.
-- Nick Budnick:
Twitter @nickbudnick
Here is the original post:
Gene therapy procedure announced in Oregon could curb hereditary diseases, raise ethical questions
bluebird bio is awarded $9.3m to support its gene therapy treatments
By Chris Reidy, Globe Staff
bluebird bio, a Cambridge company that eschews capital letters, said in a Friday press release that the California Institute for Regenerative Medicine has approved a $9.3 million award to support the development one of bluebird bios gene therapies.
The award will support the testing of a gene therapy called LentiGlobin, said the company, which also has an office in San Francisco.
LentiGlobin is designed to treat beta-thalassemia, an inherited blood disorder that causes the body to have an inadequate amount of functional hemoglobin; in its most severe form, patients typically require life-long monthly supportive red blood cell transfusions to treat their severe anemia, according to bluebird bios website.
According to bluebird bio, LentiGlobin is a one-time transformative gene therapy for patients with beta-thalassemia.
The California Institute for Regenerative Medicine was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure provided $3 billion in funding for stem cell research.
Originally posted here:
bluebird bio is awarded $9.3m to support its gene therapy treatments
bluebird bio Awarded $9.3 Million From the California Institute for Regenerative Medicine to Further Gene Therapy …
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, announced today that the California Institute for Regenerative Medicine (CIRM) has approved an award to the company for $9.3 million for the first round of its new Strategic Partnership Awards initiative. The award is to support a Phase 1/2 study to evaluate the safety and efficacy of LentiGlobin, the companys development-stage program for the treatment of beta-thalassemia, which will be initiated in the United States in 2013.
We are very encouraged by the clinical data generated to date demonstrating the potential of LentiGlobin as a one-time transformative gene therapy for patients with beta-thalassemia, said David Davidson, M.D., chief medical officer, bluebird bio. bluebird bio has made significant advances in lentiviral vector design, transduction efficiency, and in our manufacturing process, enabling the production of gene-modified products that can be scaled and deployed for many different clinical indications. We are delighted that CIRM has chosen to recognize the importance of this innovative approach for the treatment of one of the most commonly inherited blood disorders, and we are excited to work with CIRM to continue the development of LentiGlobin in the U.S.
bluebird bios LentiGlobin product introduces a fully functional human beta-globin gene into the patient's own hematopoietic stem cells. These corrected stem cells ultimately produce fully functioning red blood cells. bluebird bio is currently conducting a Phase 1/2 trial examining the feasibility, safety and efficacy of LentiGlobin in the treatment of beta-thalassemia and sickle cell disease. Results of the first patient were reported in Nature in 2010, showing dramatic results, including stable expression of functional beta-globin resulting in transfusion independence which now extends for greater than four years following a single treatment.
This CIRM award is among the first awards under the agencys Strategic Partnership Awards initiative, which is designed to engage more effectively with industry and to increase outside investment in CIRM-funded stem cell research. The funding awards were made at the October 25, 2012 meeting of the stem cell agencys governing board, the Independent Citizens Oversight Committee (ICOC).
About CIRM
CIRM was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. A list of grants and loans awarded to date may be seen here: http://www.cirm.ca.gov/for-researchers/researchfunding.
About bluebird bio
bluebird bio is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bios product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. The companys novel approach uses stem cells harvested from the patients own bone marrow into which a healthy version of the disease causing gene is inserted. bluebird bios approach represents a true paradigm shift in the treatment of severe genetic diseases by eliminating the potential complications associated with donor cell transplantation and potentially presenting a one-time transformative therapy using a patients own stem cells. bluebird bio has two later stage clinical products in development for childhood cerebral adrenoleukodystrophy (CCALD) and beta-thalassemia/sickle cell disease. Led by a world-class team, its operations are located in Cambridge, Mass., San Francisco and Paris, France. For more information, please visit http://www.bluebirdbio.com.
Read more here:
New gene therapy method tested in human cells … and it works, researchers report
ScienceDaily (Oct. 24, 2012) Oregon Health & Science University's development of a new gene therapy method to prevent certain inherited diseases has reached a significant milestone. Researchers at the university's Oregon National Primate Research Center and the OHSU Department of Obstetrics & Gynecology have successfully demonstrated their procedure in human cells. It's believed that this research, along with other efforts, will pave the way for future clinical trials in human subjects.
The research results are online Oct. 24, in the journal Nature. Dr. Mitalipov also will present the results of his research at the American Society for Reproductive Medicine Conference in San Diego Oct. 24
The OHSU gene therapy method was initially devised through research in nonhuman primates led by Shoukhrat Mitalipov, Ph.D., associate scientist in the Division of Reproductive & Developmental Sciences at ONPRC, Oregon Stem Cell Center and OHSU School of Medicine departments of Obstetrics and Gynecology and Molecular and Medical Genetics.
The procedure was specifically developed to prevent diseases related to gene defects in the cell mitochondria. Mitalipov's previous work was published in the August 2009 edition of Nature. In the current study, Mitalipov, in collaboration with Paula Amato, M.D., associate professor of obstetrics and gynecology in the OHSU Center for Women's Health, demonstrated efficacy of this therapy in human gametes and embryos.
"Cell mitochondria contain genetic material just like the cell nucleus and these genes are passed from mother to infant," explained Mitalipov. "When certain mutations in mitochondrial DNA are present, a child can be born with severe conditions, including diabetes, deafness, eye disorders, gastrointestinal disorders, heart disease, dementia and several other neurological diseases. Because mitochondrial-based genetic diseases are passed from one generation to the next, the risk of disease is often quite clear. The goal of this research is to develop a therapy to prevent transmission of these disease-causing gene mutations."
To conduct this research, Mitalipov and his colleagues obtained 106 human egg cells from study volunteers recruited through OHSU's Division of Fertility and Reproductive Endocrinology. The researchers then used a method developed in previous nonhuman primate studies, to transfer the nucleus from one cell to another. In effect, the researchers "swapped out" the cell cytoplasm, which contains the mitochondria. The egg cells were then fertilized to determine whether the transfer was a success and whether the cells developed normally. Upon inspection, it was demonstrated that it was possible to successfully replace mitochondrial DNA using this method.
"Using this process, we have shown that mutated DNA from the mitochondria can be replaced with healthy copies in human cells," explained Mitalipov. "While the human cells in our study were allowed to develop to the embryonic stem cell stage, this research shows that this gene therapy method may well be a viable alternative for preventing devastating diseases passed from mother to infant."
The current Nature paper also expanded upon the previously reported nonhuman primate work by demonstrating that the method was possible using frozen egg cells. Mitochondria were replaced in a frozen/thawed monkey egg cell, resulting in the birth of a healthy baby monkey named Chrysta.
The second portion of the study, which was completed at ONPRC, is also considered an important achievement because egg cells only remain viable for a short period of time after they are harvested from a donor. Therefore, for this therapy to be a viable option in the clinic, preservation through freezing likely is necessary so that both the donor cell and a mother's cell are viable at the time of the procedure.
While this form of therapy has yet to be approved in the United States, the United Kingdom is seriously considering its use for treating human patients at risk for mitochondria-based disease. It's believed that this most recent breakthrough, combined with earlier animal studies, will help inform that decision-making process.
More here:
New gene therapy method tested in human cells ... and it works, researchers report